SEC Comment Letter for REPLIGEN CORP (RGEN) (CIK 0000730272) (RGEN) — Aug 12, 2024
REPLIGEN CORP (RGEN) (CIK 0000730272)
Date: Aug. 12, 2024 · CIK: 0000730272 · Accession: 0000000000-24-009190
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-14656
Letter
August 12, 2024 Jason K. Garland Chief Financial Officer Repligen Corp 41 Seyon Street Bldg. 1, Suite 100 Waltham , MA 02453 Re:Repligen Corp Form 10-K for the fiscal year ended December 31, 2023 Filed February 22, 2024 File No. 000-14656 Dear Jason K. Garland: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
August 12, 2024
Jason K. Garland
Chief Financial Officer
Repligen Corp
41 Seyon Street
Bldg. 1, Suite 100
Waltham , MA 02453
Re:Repligen Corp
Form 10-K for the fiscal year ended December 31, 2023
Filed February 22, 2024
File No. 000-14656
Dear Jason K. Garland:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences